Evolus expands beyond neuromodulator competition with a 15-year exclusive deal for the hydration-focused biostimulator, no upfront fees.
Evolus has licensed exclusive U.S. distribution rights to Profhilo from IBSA under a 15-year agreement with no upfront payments—a structure that signals confidence in market uptake and ties economics to commercial success. Profhilo is a hybrid HA biostimulator (not PLLA or CaHA) that combines high-concentration hyaluronic acid with amino acids to drive skin quality and hydration rather than volume restoration.
This move diversifies Evolus beyond Jeuveau (prabotulinumtoxinA) and positions the company to capture medspa demand for skin-quality treatments that complement or compete with traditional filler protocols. Profhilo's mechanism—collagen and elastin stimulation via HA—appeals to practices seeking non-volumetric alternatives and differentiates from Galderma's Radiesse (CaHA) or AbbVie's Juvéderm Ultra (HA filler).
No upfront fees and a 15-year term signal Evolus is betting on Profhilo to compete in the skin-quality segment.
For practices, this adds another player to the injectables landscape. Evolus Rewards loyalty economics and Jeuveau pricing will likely shape how aggressively Profhilo is positioned against established filler portfolios.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
